2021 Drug Safety Communications

Current Drug Safety Communications More Drug Safety Communications

• 11-2-2021: FDA warns that getting alcohol-based hand sanitizer in the eyes can cause serious injury
• 9-01-21: FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions
• 7-20-2021: FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins
• 6-16-2021: FDA warns that vapors from alcohol-based hand sanitizers can have side effects
• 5-26-2021: Due to risk of serious liver injury, FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced cirrhosis
• 3-31-2021: Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease
• 3-25-2021: FDA warns that abuse and misuse of the nasal decongestant propylhexedrine causes serious harm
• 2-4-2021: Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib)